City of Hope Finds Aging Activates CP-As, LIFR to Drive Belly Fat in Middle Age
Updated
Updated · ScienceDaily · Jun 28
City of Hope Finds Aging Activates CP-As, LIFR to Drive Belly Fat in Middle Age
1 articles · Updated · ScienceDaily · Jun 28
Summary
City of Hope researchers found aging appears to switch on a new fat-making program, with age-specific stem cells called CP-As emerging in middle-aged tissue and rapidly generating belly fat cells.
Mouse transplant experiments showed adipocyte progenitor cells from older animals produced many new fat cells even in young mice, indicating the fat-building capacity is embedded in the aged cells themselves.
Single-cell RNA sequencing linked that shift to the LIFR signaling pathway, which the team said older mice need for CP-As to multiply and mature into fat cells, unlike young mice.
Human tissue samples also contained CP-A-like cells in greater numbers in middle-aged people, suggesting the mechanism may help explain age-related abdominal fat gain and offer a future anti-obesity drug target.
Can lifestyle changes like diet or exercise directly influence the newly discovered fat-creating stem cells in our bodies?
Is the newly discovered 'fat switch' a biological flaw of aging or a misunderstood survival mechanism from our past?
If scientists block the body's ability to create new belly fat, could the consequences be even more dangerous?
Breakthrough Discovery: CP-A Stem Cells and LIFR Pathway Identified as Key Drivers of Middle-Age Belly Fat and Metabolic Risk (2026)
Overview
Recent research has made a major breakthrough in understanding why belly fat increases with age. Scientists have identified a special type of cell, called CP-A cells, that appears in middle age and is directly linked to the rapid buildup of abdominal fat. This discovery provides a clear cellular explanation for middle-aged weight gain, moving beyond the idea that it is only caused by lifestyle choices. The activity of CP-A cells also helps explain why middle-aged adults, especially men, are more likely to develop metabolic disorders like insulin resistance and type 2 diabetes. This new understanding opens the door to targeted therapies in the future.